Abstract
Cognitive enhancers are compounds that have been purported to improve memory. Several drugs from various classes have been investigated clinically in the elderly population with different types of dementia. It is important to clarify that the dose-response relationships with these agents in the elderly population are almost nonexistent. This difficulty associated with the clinical trials in dementia patients is primarily due to problems related to quantification of the drug effect, as neuropsychological assessments have a large degree of associated measurement error. Pharmacokinetic and dynamic studies with these drugs have been few. Therefore, rather than choosing to discuss kinetics, as expected from the contributions in this part, we have decided to address methodological issues that pertain to all agents being evaluated in the elderly with some form of dementia.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alzheimer A: Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie. 1907; 64: 1460–1480.
Constantinidis J: Is Alzheimer’s disease a major form of senile dementia? Clinical, anatomical, and genetic data, in Katzman R, Terry RD, Bick KL (eds): Alzheimer’s Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, vol 7, pp 15–25.
Roth M: Diagnosis of senile and related forms of dementia, in Katzman R, Terry RD, Bick KL (eds): Alzheimer’s Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, vol 7, pp 71–85.
Petrie WM and Ban TA: Drugs in geropsychiatry. PsychopharmacolBull 1978; 14: 7–19.
Salzman C: Stimulants in the elderly, in Raskin A, Robinson DS, Levine J (eds): Age and the Pharmacology of Psychoactive Drugs. New York, Elsevier North Holland Inc, 1981, pp 171–180.
Reding MJ, Young R, DiPonte P: Amitriptyline in Alzheimer’s disease. Neurology 1983; 33: 522–523.
Cutler NR, Narang PK: Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. Psychiatr Clin North Am 1984; 7: 1–17.
Hollister LE, Yesavage J: Ergoloid mesylates for senile dementias: Unanswered questions. Ann Intern Med 1984; 100: 894–898.
Van Loveren-Huyben CMS, Engelaan HFW, Hermans MBM, Van der Born JA, Leering C, Munnichs JMA: Doubleblind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc 1984; 32: 584–588.
Epstein LJ: Anxiolytics, antidepressants, and neuroleptic patients, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1517–1523.
Coyle JT, Price DL, DeLong MR: Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190.
Terry RD, Peck A, Deteresa R, Schechter R, Horoupian DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–192.
Terry RD, Davies P: Some morphologic and biochemical aspects of Alzheimer’s disease, in Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds): Aging of the Brain. New York, Raven Press, 1983; vol 22, pp 47–59.
Carlsson A, Adolfsson R, Aquilonius SM, et al: Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism, in Goldstein M, Calne DB, Lieberman A, Thorner MO (eds): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. New York, Raven Press, 1980, pp 295–314.
Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205–242.
Yamamoto T, Hirano A: Nucleus raphe dorsalis in Alzhemer’s disease: Neurofibrillary tangles and loss of large cortical neurons. Ann Neurol 1985; 17: 573–77.
Gottfries OG, Adolfsson R, Aquilonius SM: Biochemical changes in dementia disorders of Alzheimer’s type (AD/SDAT). Neurobiol Aging 1983; 4: 261–271.
Rossor MN: Neurotransmitters in CNS disease: Dementia. Lancet 1982; 2: 200–204.
Iwangoff P, Armbruster R, Enz A, Meier-Ruge W, Sandoz P: Glycolytic enzymes from human autoptic brain cortex: Normally aged and demented cases, in Roberts PJ (ed): Biochemistry of Dementia. London and New York, John Wiley Sons, 1980, pp 258–262.
Iwangoff P, Reichlmeier K, Enz A, Meier-Ruge W: Neurochemical findings in physiological aging of the brain. Interdiscipl Topics Gerontol 1979; 15: 13–33.
Perry EK, Perry RH: The cholinergic system in Alzheimer’s disease, in Roberts PJ (ed): Biochemistry of Dementia. New York, John Wiley Sons, 1980, pp 135–183.
Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–417.
Brinkman SD, Gershon S: Measurement of cholinergic drug effects on memory in Alzheimer’s disease. Neurobiol Aging 1983; 4: 261–271.
Christie JE, Shering A, Ferguson J, Glen AIM: Physostigmine and arecholine: effects of intravenous infusion in Alzheimer presenile dementia. BrJ Psychiatry 1981; 138: 46–50.
Wettstein A, Spiegel R, Koppel-Hefti A: Therapeutic trial with the muscarinic agonist RS-86 in patients with senile dementia of Alzheimer type. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Congress, Florence, Italy, June 18–23, 1983, pp 983.
Bruno G, Mohr E, Gillespie MM, Fedio P, Chase TN: RS-86 therapy of Alzheimer’s disease. Neurology 1985; 35 (suppl 1): 265.
Zornetzer SF: Neurotransmitter modulation and memory: A new neuropharmacological phrenology? in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 637–649.
Jellinger K, Flament H, Riederer P, Schmid H, Ambrogi L: Levodopa in the treatment of (pre) senile dementia. Mech Aging Dev 1980; 14: 253–264.
Ferris SH, Reisberg B, Friedman E: Combination cholinepiracetam treatment of senile dementia. Psychopharmacol Bull 1982; 18: 94.
Cutler NR, Haxby J, Kay AD, et al: Evaluation of zimelidine in alzheimer’s disease: cognitive and biochemical measures. Arch Neurol 1985; 42: 744–748.
Davies P, Katzman R, Terry RD: Reduced somatostatinlike immunoreactivity in cerebral cortex from cases of Alzheimer’s disease and Alzheimer senile dementia. Nature 1980; 288: 279–280.
Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL: Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer’s type. Neurosci Lett 1980; 20: 373–377.
Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martia JB: Reduced numbers of somatostatin receptors in cerebral cortex in Alzheimer’s disease. Science 1985; 229: 289–291.
Delfs JR, Zhy CH, Dichter MA: Coexistence of acetylcholinesterase and somatostatinimmunoreactivity in neurons cultured from rat cerebrum. Science 1984; 223: 61–63.
Ferris SH: Neuropeptides in the treatment of Alzheimer’s disease, in Reisberg B (ed): Alzheimer’s Disease. New York, The Free Press, 1983, pp 369–373.
Veber DF, Saperstein R, Nutt RF, et al: A super active cyclic hexapeptide analog of somatostatin. Life Sci 1984; 314: 1371–1378.
Folstein MF, Folstein SE, McHugh PR: Mini-Mental State, a practical method for grading the cognitive state of patients for the clinical. J Psychiatr Res 1975; 12: 189–198.
Cutler NR, Haxby JV, Narang PK, May C, Burg C, Reines SA: Evaluation of an analogue of somatostatin (L-363,586) in Alzheimer’s disease. N Engl J Med 1985; 312: 725.
Kastin AJ, Olson GA, Sandman CA: Possible role of peptides in senile dementia, in: Crook T, Gerson S (eds): Strategies for the Development of an Effective Treatment for Senile Dementia. New Canaan, CT, Mark Powley Associates, 1981, pp 139–152.
Reisberg B, Ferris SH, Anand R: Effects of naloxone in senile dementia: a double blind trial. N Engl J Med 1983; 308: 721–722.
Blass JP, Reding MJ, Drachman E: Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer’s disease. N Engl J Med 1983; 309: 556.
Bjorklund A, Gage FH, Schmidt RH, Stenevi U, Dunnet SB: Intracerebral grafting of neuronal cell suspensions VII. Recovery of choline acetyltransferase activity and acetylcholine synthesis in the denervated hippocampus reinnervated by septal suspension implants. Acta Physiol Scand 1983; (suppl 522 ): 59–66.
Rossor MN, Iverson LL, Reynolds GP, Mountjoy CQ, Roth M: Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med 1984; 288: 961–964.
Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811.
Mattis S: Mental status examination for organic mental syndrome in the elderly patient, in Bellak L, Katasu T (eds): Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, Grune Stratton, 1976, vol 7, pp 77–121.
Thal LJ,Fuld PA, Masur DM, Sharpless NS: Oral physostigmine and lecithin improve memory in Alzheimer’s disease. Ann Neurol 1983; 13:491–495.
Wettstein A: No effect from doubleblind trial of physostigmine and lecithin in Alzheimer’s disease. Ann Neurol 1983; 13: 210–212.
Wechsler D: A standardized memory scale for clinical use. J Psychol 1945; 19: 87–95.
Benton AC: The Revised Visual Retention Test, New York, Psychological Corporation, 1974.
Benson DF: Aphasia, in Heilman EM, Valenstein E (eds): Clinical Neuropsychology. New York, Oxford University Press, 1979, pp 22–58.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Publishing Corporation
About this chapter
Cite this chapter
Cutler, N.R., Narang, P.K. (1986). Cognitive Enhancers in Alzheimer’s Disease. In: Cutler, N.R., Narang, P.K. (eds) Drug Studies in the Elderly. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1253-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1253-6_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1255-0
Online ISBN: 978-1-4684-1253-6
eBook Packages: Springer Book Archive